Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics, Inc. (TNYA)
:TNYA
RESEARCH TOOLSreports
Holding TNYA?
Track your performance easily
TNYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.99 - $7.01
Previous CloseN/A
Volume1.07M
Average Volume (3M)5.27M
Market Cap
$113.29M
Enterprise Value$101.36M
Total Cash (Recent Filing)$26.63M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.59
Next Earnings
Mar 25, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding79,220,510
10 Day Avg. Volume2,251,797
30 Day Avg. Volume5,273,145
Standard Deviation0.34
R-Squared0.18
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$22.00Price Target Upside1482.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Tenaya Therapeutics News
PremiumCompany Announcements
Tenaya Therapeutics Reports Promising TN-201 Trial Results
PremiumCompany Announcements
Tenaya Therapeutics’ Senior VP Resigns for New Opportunity
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company recently unveiled positive initial data from its Phase 1b study of TN-201, MyPeak-1.
Efficacy And SafetyPreliminary data for TN-201 showed some signs of activity and a tolerable safety profile in a severe HCM patient population.
Safety ProfileTN-401's emerging safety profile is consistent with comparable AAV gene therapies and known immunosuppressive regimens, with no cardiac adverse events reported.
Bears Say
Adverse EventsOne AE related to liver enzyme elevation was later classified as a serious adverse event (SAE) due to the steroid treatment needing to be administered in the hospital.
Cash RunwayThe company has approximately one year of cash runway, excluding a $45 million credit facility.
Financial PerformanceTNYA reported a net loss of $25.6 million for the third quarter of 2024.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TNYA FAQ
What was Tenaya Therapeutics, Inc.’s price range in the past 12 months?
Tenaya Therapeutics, Inc. lowest stock price was $0.99 and its highest was $7.01 in the past 12 months.
What is Tenaya Therapeutics, Inc.’s market cap?
Tenaya Therapeutics, Inc.’s market cap is $113.29M.
When is Tenaya Therapeutics, Inc.’s upcoming earnings report date?
Tenaya Therapeutics, Inc.’s upcoming earnings report date is Mar 25, 2025 which is in 66 days.
How were Tenaya Therapeutics, Inc.’s earnings last quarter?
Tenaya Therapeutics, Inc. released its earnings results on Nov 06, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.368 by $0.068.
Is Tenaya Therapeutics, Inc. overvalued?
According to Wall Street analysts Tenaya Therapeutics, Inc.’s price is currently Undervalued.
Does Tenaya Therapeutics, Inc. pay dividends?
Tenaya Therapeutics, Inc. does not currently pay dividends.
What is Tenaya Therapeutics, Inc.’s EPS estimate?
Tenaya Therapeutics, Inc.’s EPS estimate is -0.31.
How many shares outstanding does Tenaya Therapeutics, Inc. have?
Tenaya Therapeutics, Inc. has 79,220,510 shares outstanding.
What happened to Tenaya Therapeutics, Inc.’s price movement after its last earnings report?
Tenaya Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.368. Following the earnings report the stock price went up 12.108%.
Which hedge fund is a major shareholder of Tenaya Therapeutics, Inc.?
Among the largest hedge funds holding Tenaya Therapeutics, Inc.’s share is RA Capital Management. It holds Tenaya Therapeutics, Inc.’s shares valued at 13M.
---
Tenaya Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (1482.73% Upside)
$22.00 (1482.73% Upside)
Hedge Fund Trend
Decreased
By 743.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.55%
12-Months-Change
Fundamentals
Return on Equity
-84.49%
Trailing 12-Months
Asset Growth
-27.31%
Trailing 12-Months
Company Description
Tenaya Therapeutics, Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
---
TNYA Stock 12 Month Forecast
Average Price Target
$22.00
▲(1482.73% Upside)
Technical Analysis
Allogene Therapeutics
―
Fate Therapeutics
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Beam Therapeutics
―
Best Analysts Covering TNYA
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-24.65%
reiterated a buy rating 2 months ago
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -24.65% per trade.
---